Cryo-Cell International, Inc. (CCEL) Financial Ratios
29 years of historical data (1996–2024) · Healthcare · Medical - Care Facilities
EV/EBITDA
↑
10.30
↓-24% vs avg
5yr avg: 13.59
30Y Low6.9·High56.6
P/FCF
↑
7.88
↓-81% vs avg
5yr avg: 42.09
30Y Low6.6·High139.9
P/B Ratio
N/A
—
5yr avg: 24.74
30Y Low2.1·High110.7
ROE
↓
N/A
—
5yr avg: 241.3%
30Y Low-248%·High274%
Debt/EBITDA
↑
3.26
↑+100% vs avg
5yr avg: 1.63
30Y Low0.4·High17.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CCEL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cryo-Cell International, Inc. trades at 70.6x earnings, 12% above its 5-year average of 63.2x, sitting at the 86th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 219%. On a free-cash-flow basis, the stock trades at 7.9x P/FCF, 81% below the 5-year average of 42.1x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $28M | $71M | $45M | $37M | $104M | $61M | $64M | $55M | $62M | $34M | $32M |
| Enterprise Value | $41M | $84M | $55M | $47M | $98M | $57M | $66M | $62M | $63M | $41M | $29M |
| P/E Ratio → | 70.60 | 173.40 | — | 13.24 | 49.52 | 16.67 | 27.96 | — | 26.87 | — | 3.98 |
| P/S Ratio | 0.89 | 2.23 | 1.42 | 1.22 | 3.58 | 1.96 | 2.00 | 1.87 | 2.43 | 1.49 | 1.53 |
| P/B Ratio | — | — | — | — | 24.74 | — | — | — | — | — | — |
| P/FCF | 7.88 | 19.74 | 34.84 | — | 106.18 | 7.62 | 11.22 | 11.66 | 10.98 | 7.42 | 6.82 |
| P/OCF | 4.73 | 11.85 | 5.00 | 4.32 | 13.06 | 7.21 | 10.04 | 10.24 | 10.79 | 6.91 | 6.66 |
P/E links to full P/E history page with 30-year chart
CCEL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Cryo-Cell International, Inc.'s enterprise value stands at 10.3x EBITDA, 24% below its 5-year average of 13.6x. The Healthcare sector median is 14.1x, placing the stock at a 27% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.61 | 1.76 | 1.55 | 3.40 | 1.83 | 2.07 | 2.11 | 2.47 | 1.76 | 1.39 |
| EV / EBITDA | 10.30 | 21.08 | — | 8.05 | 18.35 | 6.86 | 12.07 | 11.17 | 11.97 | 56.65 | 9.25 |
| EV / EBIT | 11.73 | 88.96 | — | 9.71 | 24.58 | 8.65 | 12.94 | 11.91 | 12.73 | — | 13.02 |
| EV / FCF | — | 23.17 | 43.03 | — | 100.60 | 7.10 | 11.65 | 13.13 | 11.16 | 8.78 | 6.19 |
CCEL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cryo-Cell International, Inc. earns an operating margin of 10.9%. Operating margins have compressed from 13.3% to 10.9% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.2% | 75.2% | 73.1% | 71.0% | 68.9% | 69.0% | 68.5% | 70.8% | 73.5% | 75.0% | 73.3% |
| Operating Margin | 10.9% | 10.9% | -39.3% | 13.3% | 13.9% | 24.6% | 15.9% | 17.8% | 19.7% | 1.9% | 13.9% |
| Net Profit Margin | 1.3% | 1.3% | -30.4% | 9.1% | 7.2% | 11.6% | 7.2% | -2.9% | 9.1% | -5.7% | 38.4% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | 208.4% | 274.3% | — | — | — | — | — | — |
| ROA | 0.6% | 0.6% | -15.1% | 4.4% | 3.9% | 8.1% | 5.4% | -2.6% | 10.7% | -6.8% | 54.6% |
| ROIC | — | — | -235.3% | 84.7% | — | — | — | — | — | — | — |
| ROCE | 8.3% | 8.3% | -28.7% | 9.5% | 11.6% | 26.8% | 18.6% | 28.1% | 61.1% | 5.6% | 57.8% |
CCEL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Cryo-Cell International, Inc. carries a Debt/EBITDA ratio of 3.3x, which is moderately leveraged (roughly in line with the sector average of 3.3x). Net debt stands at $12M ($13M total debt minus $560960 cash). Interest coverage of just 1.9x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.67 | — | — | — | — | — | — |
| Debt / EBITDA | 3.26 | 3.26 | — | 1.99 | 0.53 | 0.75 | 1.64 | 2.35 | 1.39 | 13.63 | 0.37 |
| Net Debt / Equity | — | — | — | — | -1.30 | — | — | — | — | — | — |
| Net Debt / EBITDA | 3.12 | 3.12 | — | 1.70 | -1.02 | -0.50 | 0.44 | 1.25 | 0.19 | 8.77 | -0.94 |
| Debt / FCF | — | 3.43 | 8.19 | — | -5.58 | -0.51 | 0.43 | 1.47 | 0.18 | 1.36 | -0.63 |
| Interest Coverage | 1.87 | 1.87 | -9.95 | 2.64 | 2.91 | 4.96 | 2.97 | 3.35 | 3.84 | 0.46 | 2.25 |
CCEL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.58x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.49x to 0.58x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.58 | 0.58 | 0.45 | 0.49 | 0.75 | 1.13 | 1.00 | 1.91 | 0.91 | 0.69 | 0.99 |
| Quick Ratio | 0.55 | 0.55 | 0.42 | 0.45 | 0.71 | 1.07 | 0.93 | 0.87 | 0.89 | 0.66 | 0.95 |
| Cash Ratio | 0.16 | 0.16 | 0.05 | 0.09 | 0.40 | 0.64 | 0.48 | 0.45 | 0.48 | 0.31 | 0.46 |
| Asset Turnover | — | 0.49 | 0.51 | 0.47 | 0.48 | 0.67 | 0.74 | 0.69 | 1.06 | 1.18 | 1.08 |
| Inventory Turnover | 12.08 | 12.08 | 10.98 | 10.33 | 9.76 | 10.41 | 9.25 | 0.53 | 21.38 | 15.99 | 11.84 |
| Days Sales Outstanding | — | 83.41 | 76.58 | 72.72 | 66.38 | 74.09 | 69.95 | 73.30 | 73.70 | 63.96 | 52.93 |
CCEL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cryo-Cell International, Inc. returns 12.0% to shareholders annually — split between a 7.0% dividend yield and 5.0% buyback yield. The payout ratio exceeds 100% at 502.5%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 1.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 7.0% | 2.8% | — | 20.7% | — | — | — | — | — | — | — |
| Payout Ratio | 502.5% | 502.5% | — | 276.9% | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 0.6% | — | 7.6% | 2.0% | 6.0% | 3.6% | — | 3.7% | — | 25.2% |
| FCF Yield | 12.7% | 5.1% | 2.9% | — | 0.9% | 13.1% | 8.9% | 8.6% | 9.1% | 13.5% | 14.7% |
| Buyback Yield | 5.0% | 2.0% | 1.8% | 4.9% | 0.2% | 0.0% | 1.6% | 0.0% | 0.7% | 31.3% | 9.9% |
| Total Shareholder Yield | 12.0% | 4.8% | 1.8% | 25.6% | 0.2% | 0.0% | 1.6% | 0.0% | 0.7% | 31.3% | 9.9% |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | $10M |
Peer Comparison
Compare CCEL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CCELYou | $28M | 70.6 | 10.3 | 7.9 | 75.2% | 10.9% | — | — | 3.3 |
 VCEL | $2B | 114.9 | 652.8 | 35.9 | 74.4% | 4.0% | 5.1% | 2.5% | 33.8 |
 BLFS | $1B | -87.0 | — | 52.1 | 64.6% | -12.6% | -3.4% | -2.7% | — |
 IART | $1B | -2.1 | 13.2 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 OSUR | $216M | -3.2 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
 BDX | $52B | 24.8 | 14.0 | 19.6 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 TECH | $7B | 103.1 | 36.3 | 28.9 | 64.8% | 8.4% | 3.7% | 3.4% | 2.1 |
 FELE | $4B | 31.1 | 14.0 | 23.0 | 35.5% | 12.7% | 11.3% | 14.7% | 0.8 |
 LMAT | $3B | 43.7 | 34.1 | 33.7 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See CCEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CCEL vs VCEL
Side-by-side business, growth, and profitability comparison vs Vericel Corporation.
Start ComparisonCCEL — Frequently Asked Questions
Quick answers to the most common questions about buying CCEL stock.
What is Cryo-Cell International, Inc.'s P/E ratio?
Cryo-Cell International, Inc.'s current P/E ratio is 70.6x. The historical average is 40.1x. This places it at the 86th percentile of its historical range.
What is Cryo-Cell International, Inc.'s EV/EBITDA?
Cryo-Cell International, Inc.'s current EV/EBITDA is 10.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.2x.
Is CCEL stock overvalued?
Based on historical data, Cryo-Cell International, Inc. is trading at a P/E of 70.6x. This is at the 86th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Cryo-Cell International, Inc.'s dividend yield?
Cryo-Cell International, Inc.'s current dividend yield is 6.97% with a payout ratio of 502.5%.
What are Cryo-Cell International, Inc.'s profit margins?
Cryo-Cell International, Inc. has 75.2% gross margin and 10.9% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Cryo-Cell International, Inc. have?
Cryo-Cell International, Inc.'s Debt/EBITDA ratio is 3.3x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.